PD-L1 Antibodies

Target Information

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. Belongs to the immunoglobulin superfamily. BTN/MOG family. Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes. 3 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.

Alternate Names

A530045L16Rik; B7 homolog 1; B7-H; B7-H1; B7H1; B7h1; CD274; Cd274; CD274 antigen; CD274 molecule; hPD-L1; MGC142294; MGC142296; OTTMUSP00000015826; PD-; PD-L1; PD1L1; PDCD1 ligand 1; Pdcd1l; PDCD1L1; Pdcd1l1; PDCD1LG1; Pdcd1lg1; PDL1; Pdl1; Programmed cell death 1 ligand 1; Programmed death ligand 1